- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05893758
Lifetech Cera™ PFO Occluder Post-Market Clinical Follow-Up
December 26, 2023 updated by: Lifetech Scientific (Shenzhen) Co., Ltd.
A Real-world Registry Assessing the Clinical Use of the Lifetech Cera™ PFO Occluder
The objective of this post-market registry is to assess the clinical use of the Lifetech Cera™ PFO Occluder in a real-world and on-label fashion.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study intends to collect data from patients who have implanted with the device between 2019 to 2022.
It is estimated to start enrollment in Sep 2023 and complete by end of 2024.
Final report shall be completed in 2025.
Study Type
Observational
Enrollment (Estimated)
94
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rae Gong
- Phone Number: (86-755)-86026250-6957
- Email: gongrui@lifetechmed.com
Study Locations
-
-
-
Gliwice, Poland
- Not yet recruiting
- Szpital Miejski Nr 4 w Gliwicach
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Myszków, Poland
- Recruiting
- Oddział Kardiologii, Pracownia Hemodynamiki, Oddział Intensywnego Nadzoru Kardiologicznego oraz Pracownia Elektrofizjologii w Szpitalu w Myszkowie G.V.M.Carint
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Oświęcim, Poland
- Recruiting
- Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii G.V.M.Carint-Oświęcim
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Sanok, Poland
- Not yet recruiting
- Podkarpackie Centrum Interwencji Sercowo- naczyniowej G.V.M.Carint -Sanok
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Tychy, Poland
- Recruiting
- Polsko-Amerykańskie Kliniki Serca, Centrum Sercowo- Naczyniowe w Tychach, Grupa American Heart of Poland
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Ustroń, Poland
- Recruiting
- Polsko-Amerykańskie Kliniki Serca I Oddział Kardiologii Inwazyjnej i Niewydolności Serca w Ustroniu, Grupa AHoP
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
Zakopane, Poland
- Recruiting
- Szpital Powiatowy im. dr Tytusa Chałubińskiego w Zakopanem
-
Contact:
- Przemyslaw Weglarz
-
Contact:
- Ewa K Kuszewska
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with a confirmed diagnosis of Patent Foramen Ovale (PFO) which is associated with TIA or cryptogenic stroke, and implanted with the investigational device.
Description
Inclusion Criteria:
- Patients with a confirmed diagnosis of Patent Foramen Ovale (PFO);
- Associated with TIA or cryptogenic stroke;
- Patients was implanted with the investigational device as per IFU instructions;
- Patients or legally authorized representatives have signed Data Release Consent or equivalent documents.
Exclusion Criteria:
- Any contraindication mentioned in the corresponding IFU;
- Patients did not conduct any follow up visit after hospital discharge.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PFO subjects
Patients with a confirmed diagnosis of Patent Foramen Ovale (PFO) which is associated with TIA or cryptogenic stroke, and implanted with the investigational device.
|
The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of stroke/TIA, procedure/device-related death and serious procedure/device complications
Time Frame: from attempted procedure to 24 months post-implantation.
|
Serious procedure/device complications include device embolization, cardiac or vascular perforation, atrial fibrillation, device thrombosis, pulmonary embolism and deep vein thrombosis.
|
from attempted procedure to 24 months post-implantation.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Successful closure of the PFO, confirmed by contrast Transcranial Doppler (cTCD), defined as with no, small or moderate residual shunt
Time Frame: at procedure, 6 months and 12 months post-implantation
|
at procedure, 6 months and 12 months post-implantation
|
Incidence of device or procedure related Adverse Events (AEs)
Time Frame: from attempted procedure to 24 months post-implantation
|
from attempted procedure to 24 months post-implantation
|
Incidence of device or procedure related Serious Adverse Events (SAEs)
Time Frame: from attempted procedure to 24 months post-implantation
|
from attempted procedure to 24 months post-implantation
|
Incidence of Device Deficiencies (DD)
Time Frame: from attempted procedure to 24 months post-implantation
|
from attempted procedure to 24 months post-implantation
|
Incidence of death
Time Frame: from attempted procedure to 24 months post-implantation
|
from attempted procedure to 24 months post-implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
May 30, 2023
First Submitted That Met QC Criteria
May 30, 2023
First Posted (Actual)
June 8, 2023
Study Record Updates
Last Update Posted (Estimated)
January 1, 2024
Last Update Submitted That Met QC Criteria
December 26, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT-TS-275-2023-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patent Foramen Ovale
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
Carag AGCompleted
-
W.L.Gore & AssociatesRecruitingStroke | PFO - Patent Foramen OvaleUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruitingMigraine | PFO - Patent Foramen OvaleChina
-
Wolfson Medical CenterUnknownClosure of the Foramen Ovale and Ductus ArteriosusIsrael
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of OregonEnrolling by invitationPatent Foramen OvaleUnited States
-
Lifetech Scientific (Shenzhen) Co., Ltd.CompletedPatent Foramen OvaleIreland, Germany
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
Clinical Trials on The Cera™ PFO Occluder
-
Cardiac Children's Foundation TaiwanRecruiting
-
Abbott Medical DevicesRecruitingStroke | Patent Foramen OvaleUnited States, Germany, Canada, Switzerland, Italy, Portugal, United Kingdom
-
SeptRx, Inc.UnknownHeart Septal Defects | Heart Defects, Congenital | Foramen Ovale, PatentGermany, France
-
China National Center for Cardiovascular DiseasesRecruiting
-
Abbott Medical DevicesApproved for marketingPatent Foramen Ovale | PFO
-
Nobles Medical Technologies II IncSuspendedForamen Ovale, Patent | Stroke, IschemicUnited States, Italy
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
Lifetech Scientific (Shenzhen) Co., Ltd.CompletedPatent Foramen OvaleIreland, Germany
-
Abbott Medical DevicesRecruitingPFO - Patent Foramen Ovale | VSD - Muscular Ventricular Septal Defect | PIVSD - Post Infarct Muscular Ventricular Septal Defect | ASD - Atrial Septal DefectSpain, Germany, Poland, France, Italy, Netherlands, Switzerland